Short Interest in OSR Holdings, Inc. (NASDAQ:OSRH) Drops By 38.1%

OSR Holdings, Inc. (NASDAQ:OSRH) was the recipient of a significant drop in short interest in July. As of July 31st, there was short interest totaling 1,048,980 shares, a drop of 38.1% from the July 15th total of 1,693,343 shares. Approximately 4.7% of the company’s stock are sold short. Based on an average daily volume of 705,294 shares, the days-to-cover ratio is presently 1.5 days.

Hedge Funds Weigh In On OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP acquired a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR at the end of the most recent reporting period. 55.30% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

OSRH has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of OSR from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, OSR currently has an average rating of “Sell”.

OSR Stock Down 13.2%

NASDAQ:OSRH opened at $0.37 on Thursday. The stock’s 50 day moving average price is $0.39 and its two-hundred day moving average price is $0.47. The firm has a market capitalization of $13.10 million, a price-to-earnings ratio of -1.01 and a beta of 0.56. OSR has a 12-month low of $0.25 and a 12-month high of $1.24.

OSR (NASDAQ:OSRH) last issued its earnings results on Friday, August 14th. The company reported ($0.02) EPS for the quarter. The business had revenue of $0.32 million for the quarter. OSR had a negative return on equity of 8.36% and a negative net margin of 593.15%.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.